Annexon will present new phase 3 data from its ARCHER and ARCHER II geographic atrophy trials at the Retina Society’s 59th Annual Scientific Meeting. Two presentations will include baseline characteristics, marking continued progress in its clinical program.
published
Annexon will present new phase 3 data from its ARCHER and ARCHER II geographic atrophy trials at the Retina Society’s 59th Annual Scientific Meeting. Two presentations will include baseline characteristics, marking continued progress in its clinical program.
Latest documented BWB result
$NBIS market result
Exit $NBIS with $3.25 profit per contract
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.